Introduction
Typical absence seizures (AS) constitute about 10% of seizures in children with epilepsy. The Commission on Classification and Terminology of the International League Against Epilepsy 1 recognises four epileptic syndromes with typical AS: childhood absence epilepsy; juvenile absence epilepsy; juvenile myoclonic epilepsy and myoclonic absence epilepsy. Valproate and ethosuximide are the most commonly used drugs for AS. Non-systematic reviews have suggested that ethosuximide and sodium valproate are equally effective. 2 Valproate is considered the drug of choice in juvenile myoclonic epilepsy, 3, 4 although there is little in the way of evidence from randomized controlled trials to support this. 5 Lamotrigine used to be considered a second line drug, reserved for intractable AS, 2 but its use has increased with time. It is especially valued in situations where sodium valproate leads to weight gain and also for women of childbearing Seizure (2005) age. The latter is due to concern about a higher rate of fetal abnormalities in pregnancies exposed to valproate. 6 Preliminary studies suggested that lamotrigine may become a first line drug in AS. 7 This review aims to determine the best choice of anticonvulsant for children and adolescents with typical AS by reviewing the information available from randomized controlled trials.
Methods
Trials were included if they met the following criteria:
(1) Randomised parallel group monotherapy or addon trials which recruited children or adolescents with AS. (2) Trials used adequate or quasi methods (e.g. allocation by day of week) of randomisation. (3) Sodium valproate, ethosuximide or lamotrigine as monotherapy or add-on treatment were compared with placebo or with one another.
Outcomes were:
(1) Proportion of participants seizure free at 1, 6 and 18 months after randomisation. No language restriction was used. In addition, we contacted Sanofi Winthrop, Glaxo Wellcome and Parke Davis, manufacturers of sodium valproate, lamotrigine and ethosuximide, respectively. We also reviewed any references of identified studies and retrieved any relevant studies. Two authors (EP and KM) independently assessed trials for inclusion and disagreements were resolved by discussion. The same two reviewers independently extracted data from trial reports
Analysis
The data for our chosen outcomes are dichotomous and our preferred outcome statistic was the relative risk. We assessed clinical heterogeneity by comparing trial design, participant population and outcomes across trials. We assessed statistical heterogeneity using a chi squared test for heterogeneity. Due heterogeneity and other methodological problems associated with the studies meeting our inclusion criteria, it was not possible to summarise results in a meta-analysis.
Four trials met our inclusion criteria. No report described the method of randomization concealment, two trials were double blind 8, 10 and two were unblinded. 9, 11 Two reports describe losses to follow up and exclusions from analyses. 8, 10 No explicit statement about losses to follow up are made for the other two trials. All four trials used outcomes that included EEG, hyperventilation EEG and/or video telemetry as the ways of assessing outcome in addition to clinical observations. Further details of included trials are given below and in Table 1 .
Results

Lamotrigine versus placebo
Frank and colleagues 8 report a double blinded RCT that compared lamotrigine with placebo. This trial used a 'responder enriched' design and hence compares the effect of continuing versus withdrawing lamotrigine. Participants (total 29, aged 3-15 years) had newly diagnosed typical AS. Prior to randomization all participants received treatment with lamotrigine. After 4 weeks or more of treatment, participants who were seizure free and had a negative 24-h EEG with hyperventilation, were randomized to either continue lamotrigine or to placebo and were followed up for 4 weeks. One participant withdrew consent immediately following randomization and before treatment was started, but was accounted for in analyses. In the initial open label dose escalation phase 71% of the participants became seizure free on lamotrigine, which was assessed using a 24-h EEG/video telemetry recording. Following randomization, 64% of the participants on lamotrigine remained seizure free versus 21% on the placebo (P < 0.03).
Valproate versus ethosuximide
We found three studies comparing valproate with ethosuximide. 9, 11, 10 Callaghan et al. 9 report an open parallel group RCT that compared monotherapy with ethosuximide and sodium valproate. Participants (total 28, aged 4-15 years) had typical AS and were previously untreated. Follow-up ranged from 18 months to 4 years. Martinovic 10 reports an open parallel group RCT comparing ethosuximide and sodium valproate. Participants (total 20, aged 5-8 years) were said to have simple absences with onset less that 6 weeks prior to randomization and were followed up for 1-2 years. Six participants were excluded from analyses.
Sato et al. 11 report an RCT with a complex response conditional design and recruited drug naive as well as participants already on treatment. In the first phase of this trial, participants (total 45, aged 3-18 years) were randomized to receive either valproate (and placebo ethosuximide) or ethosuximide (and placebo valproate) and followed up for 6 weeks. Participants responding to randomized treatment continued with the randomized drug for a further 6 weeks. Responders were defined as previously untreated participants who became seizure free or participants who had been previously treated and had an 80% or greater reduction in AS frequency. Non-responders and those with adverse effects were crossed over to the alternative treatment and followed up for a further 6 weeks. Apart from AS some participants also had other types of seizures. The report does not specify if the absence seizures were typical or atypical.
Due to differences in study design, participants, and length of follow-up we did not think it appropriate to pool results in a meta-analysis. For our chosen outcome 'seizure freedom', we were unable to extract data for this outcome at the time points we had specified (1, 6 and 18 months). Rather than not present any data for this outcome, we have summarised results for individual trials, where the proportion of participants seizures free during follow-up was reported.
Results for individual studies are presented below as well as in Fig. 1 .
Seizure freedom
The relative risk (RR) estimates with 95% confidence intervals (CI) for seizure freedom (RR < 1 favours ethosuximide) are: Hence none of these trials found a difference for this outcome. However, confidence intervals are all wide and the possibility of important differences has not been excluded and equivalence cannot be inferred.
Eighty percent or greater reduction in seizure frequency
This outcome was only reported by Sato et al., 11 and the RR was 0.70 (95% CI 0.19-2.59). Again no difference is found, but the confidence interval is wide and equivalence cannot be inferred.
Fifty percent or greater reduction in seizure frequency
This was reported for two trials. In one trial (10) all participants achieved this outcome. For the other trial (9) the RR was 1.02 (95% CI 0.70-1.48). Again no difference is found, but the confidence interval is wide and equivalence cannot be inferred.
Adverse effects
The most common adverse effects of treatment with valproate reported by the three studies were thrombocytopenia, nausea, vomiting, drowsiness and leukopenia. Adverse effects often seen with valproate treatment are dyspepsia, weight gain, tremor, transient hair loss and hematological abnormalities. Ethosuximide treatment was associated with drowsiness, nausea, vomiting, leukopenia and tiredness. In the lamotrigine study 8 a common adverse event was rash. Only in one of the patients this was thought to be related to lamotrigine. There were two serious adverse events during the treatment but they were judged to be unrelated to treatment. Side effects related to nervous system were common (reported by 5% or more of participants): asthenia, headache, dizziness and hyperkinesias. Other reported complaints were abdominal pain, nausea, and anorexia.
Discussion
Despite absence seizures being relatively common in children, we found only four randomised controlled trials, into which 20-45 participants were recruited. One trial compared lamotrigine with placebo, whilst the other three compared ethosuximide with valproate. The description of methodology was inadequate, and none of the trial reports gave a description of allocation concealment. Two trials were double blinded, and in only two trials was there a mention of losses to follow-up or exclusions from analyses. The four trials used a variety of methodologies; two were parallel trials 9,10 and the other two used response conditional designs. The length of follow-up ranged from 4 weeks to 4 years.
The trial comparing lamotrigine and placebo found that individuals becoming seizure free on lamotrigine, were significantly more likely to remain seizure free if they were randomized to stay on lamotrigine rather than placebo. In essence, this trial assessed the effect of lamotrigine withdrawal. Although this trial finds evidence of an effect of lamotrigine upon absence seizures, it was of only 4 weeks duration, and the design of the trial does not reflect or inform clinical practice. There are no placebo controlled trials of ethosuximide or valproate, and hence no placebo controlled data to support an effect of either drug on AS. Current practice is based largely upon evidence derived from observational and anecdotal evidence, and it is now unlikely that placebo controlled trials will ever be undertaken with these drugs.
Placebo controlled trials will usually provide the most convincing evidence that a drug has an effect, in this case upon absence seizures. The information provided by placebo controlled trials is particularly helpful to drug regulatory authorities. Placebo controlled trials, however, have a number of limitations in terms of informing clinical practice. This is particularly so when there are a number of potential treatments available, and the clinician and patient want to know how the available treatments compare with each other. Information that informs this decision will come from trials in which drugs have been compared head to head.
We did find trials comparing valproate and ethosuximide head to head. Due to the differing methodologies used, we thought it inappropriate to undertake a meta-analysis. None of the trials found a difference between these two drugs, however confidence intervals were wide and the possibility of important differences was not excluded. Hence they lacked the power to find equivalence.
In summary, ethosuximide, lamotrigine and valproate are commonly used to treat children and adolescents with absence seizures. We have some evidence from one trial that lamotrigine has an effect on seizures, but the trial was not designed to reflect or inform clinical practice. There is no evidence from randomised controlled trials that ethosuximide or valproate have an effect on absence seizures, and we have no evidence from randomised controlled trials upon which to base a choice between these drugs.
Conclusion
Further trials are required if we are to have a reliable evidence base upon which to inform clinical practice. It is important that we understand the effects of our standard drugs such as ethosuximide, valproate and lamotrigine, as there are an increasing number of newer antiepileptic drugs, the effects of which will need to be compared with a standard treatment.
Placebo controlled trials in people with newly diagnosed AS will provide evidence of a treatment effect, the main purpose of which is to inform drug regulatory authorities. Ethical concerns have been raised however regarding placebo controlled monotherapy trials in epilepsy, 13 although the debate has centered primarily around adult patients prone to more significant seizure types (tonic clonic seizures) for whom withholding treatment would put them at risk of injury. We are not aware of any debate regarding the ethical acceptability of placebo controlled trials recruiting children with AS and a debate may now be required.
It is trials comparing one drug with another that are most required to better inform clinical practice. These trials should be pragmatic in concept and given that absence seizures are relatively common they should be feasible. Such trials will need to be of at least 12 months' duration and measure outcomes which include remission from seizures, EEG with a hyperventilation test, adverse effects, quality of life and psychosocial outcomes.
